Akebia Therapeutics Inc AKBA

US Biotechnology

$0.54 ▲ +1.13% (+$0.01)

Open $0.53

Prev Close $0.53

Day Range $0.49 – $0.55

52W Range $0.36 – $2.11

Market Cap $147.94M

Beta 0.35

EPS (TTM) $-0.11

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-03-20
Shares Out.	277,110,000
Website	akebia.com/ ↗
Phone	13026587581
Employees	194
Revenue	$36.9M
Gross Profit	$30.5M
Net Income	-$14.4M
Free Cash Flow	$13.9M
Total Assets	$342.1M
Total Liabilities	$321.8M
Equity	$20.4M

About Akebia Therapeutics Inc

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Inc is a publicly traded company under the ticker symbol AKBA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.